Literature DB >> 4563662

Mazindol, a new non-amphetamine anorexigenic agent.

A J Hadler.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4563662     DOI: 10.1002/j.1552-4604.1972.tb00246.x

Source DB:  PubMed          Journal:  J Clin Pharmacol New Drugs        ISSN: 0021-9754


× No keyword cloud information.
  7 in total

Review 1.  Pharmacological approaches for the treatment of obesity.

Authors:  José-Antonio Fernández-López; Xavier Remesar; Màrius Foz; Marià Alemany
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Testicular pain caused by mazindol.

Authors:  J McEwen; R H Meyboom
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

Review 3.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

Review 4.  Anorectic drugs: use in general practice.

Authors:  D Craddock
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 5.  A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.

Authors:  R B Rothman; J R Glowa
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

6.  Pilot Phase II study of mazindol in children with attention deficit/hyperactivity disorder.

Authors:  Eric Konofal; Wei Zhao; Cédric Laouénan; Michel Lecendreux; Florentia Kaguelidou; Lila Benadjaoud; France Mentré; Evelyne Jacqz-Aigrain
Journal:  Drug Des Devel Ther       Date:  2014-12-01       Impact factor: 4.162

Review 7.  Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.

Authors:  Rosa Camila Lucchetta; Bruno Salgado Riveros; Roberto Pontarolo; Rosana Bento Radominski; Michel Fleith Otuki; Fernando Fernandez-Llimos; Cassyano Januário Correr
Journal:  Clinics (Sao Paulo)       Date:  2017-05       Impact factor: 2.365

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.